MedTrace Logo

Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma

NCT00006480 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2010-09-21

No results posted yet for this study

Summary

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Inserting genetic material made in the laboratory into a person's blood cells may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I trial to study the effectiveness of biological therapy and gene therapy in treating children who have recurrent or refractory neuroblastoma.

Conditions

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

therapeutic autologous lymphocytes

DRUG

chemotherapy

DRUG

ganciclovir

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Julie R. Park, MD · Fred Hutchinson Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
1 Year
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Completion
2005-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006480 on ClinicalTrials.gov